EBITDA Jumps 40% YoY to ₹352.1 Cr; PAT Rises 33% to ₹201.6 Cr Amid Portfolio Expansion
Granules India Ltd., a vertically integrated pharmaceutical powerhouse, reported stellar Q4 FY26 results, with revenue from operations soaring 23% year-on-year to ₹14,706 million (₹1,470.6 crore). This marks strong momentum in finished dosages and peptides CDMO, boosting EBITDA 40% to ₹3,521 million and PAT 33% to ₹2,016 million.
Quarterly Consolidated Financials (₹ Mn)
| Metric | Q4 FY26 | Q3 FY26 (QoQ Growth) | Q4 FY25 (YoY Growth) |
|---|---|---|---|
| Revenue from Operations | 14,706 | 13,879 (+6%) | 11,974 (+23%) |
| EBITDA (Margin) | 3,521 (24%) | 3,081 (22%) (+14%) | 2,524 (21%) (+40%) |
| PBT (Before Exceptional) | 2,464 | 2,022 (+22%) | 1,668 (+48%) |
| PAT (Margin) | 2,016 (14%) | 1,502 (11%) (+34%) | 1,520 (13%) (+33%) |
Annual Consolidated Financials (₹ Mn, YoY Growth)
- Revenue from Operations: ₹53,656 (+20%)
- EBITDA (Margin): ₹11,851 (22%) (+25%)
- PBT (Before Exceptional): ₹7,950 (+26%)
- PAT: ₹5,950 (+19%) at 11% margin
Business Highlights:
- North America: 72% revenue share (down from 79% YoY); Europe: 17% (up from 8%).
- Revenue Mix: Finished Dosages (73%), APIs (13%), PFIs (9%), Peptides/CDMO (5%).
- ROCE: Improved to 17.6% (FY25: 16.6%).
- Balance Sheet: Net debt ₹4,021 Mn (down ₹3,040 Mn YoY); Net debt/EBITDA: 0.34x.
Dr. Krishna Prasad Chigurupati, Chairman & Managing Director, commented, “We delivered a strong performance in Q4FY26, driven by continued portfolio expansion, disciplined execution, and steady progress across regulatory, compliance, and sustainability initiatives. The quarter reflects improving earnings quality and sustained advancement in Complex Generics and the Peptides CDMO platform.”
Granules India (BSE: 532482, NSE: GRANULES), headquartered in Hyderabad, operates 10 global facilities with approvals from the US FDA, EDQM, and others, serving 300+ customers in 80+ countries.
